Global Venous Stents Market 2025–2034

Reports Description

Global Venous Stents Market size was valued at USD 1,440.6 Million in 2025 and is projected to reach USD 2,987.7 Million by 2034, growing at a CAGR of 11.40% from 2024 to 2034 during the forecast period 2025 – 2034.

Venous Stents Market: Overview

Venous stents (VS) are employed to address central and peripheral venous stenosis. Venous injury, inflammation, turbulent flow, and uremia can all contribute to developing these stenoses. Venous stenoses are especially problematic when they are linked to hemodialysis access for a patient with end-stage renal disease.

These stents can treat conditions that obstruct blood flow or induce chronic blood clots in the abdomen, thorax, or legs. Venous stenting is employed as an adjunctive therapy in patients with acute iliofemoral deep vein disease when residual venous occlusion (RVOO) persists following balloon angioplasty and thrombolysis.

The objective is to restore vascular patency and prevent post-thrombotic syndrome (PTS). They are inserted into a narrowed or obstructed vein and function as scaffolds, maintaining the vein’s openness and enhancing blood flow.

Venous stenting is a minimally invasive procedure that has gained popularity as a treatment for conditions including chronic venous insufficiency, deep vein thrombosis, and venous leg ulcers.. The procedure has become more effective and safer due to stent technology and materials advancements.

Venous Stents Market: Growth Factors

Various factors can influence the market drivers for the Venous Stents Market. These may encompass:

• The venous stent market is being driven by the increasing prevalence of venous disorders, including chronic venous insufficiency (CVI), venous ulcers, and deep vein thrombosis (DVT). With the increasing prevalence of these issues, venous stents are becoming increasingly essential for managing and treating these conditions.

• Venous, more efficient and resilient stents have been developed due to ongoing advancements in stent architecture and composition. These advancements enhance the radial strength, flexibility, and resistance to compression of stents in the venous system, thereby extending their lifespan and efficacy.

• The market for venous stents has been stimulated by the increase in the use of minimally invasive procedures to treat venous disorders. Patients favor these procedures due to their reduced discomfort, reduced recuperation time, and reduced likelihood of complications compared to conventional open surgeries.

• The demand for venous stents is higher due to the increased prevalence of venous disorders among the elderly. The prevalence of venous maladies and the aging of the global population will likely result in a greater need for venous stents.

• These conditions’ early identification and treatment have been made possible by advancements in diagnostic methods and a deeper comprehension of venous diseases. As a result, there is a greater demand for venous stents to manage and treat these conditions effectively. The healthcare infrastructure of developing countries is improving, resulting in a greater availability of advanced venous treatments. Consequently, the market has experienced growth due to the increased use of venous stents in these regions.

• The market for venous stents has been bolstered by the availability of favorable payment plans in numerous countries, encouraging patients to seek treatment.

Venous Stents Market: Limitations

Numerous factors can serve as obstacles or constraints for the Venous Stents Market. These may encompass:

• Inadequate Understanding: One of the primary obstacles is the lack of awareness among patients and healthcare professionals regarding venous disorders and the numerous treatment options, including the use of venous catheters. This ignorance may lead to the underdiagnosis and undertreatment of vein disorders.

• Cost: The expense of venous stents can significantly impede their use, particularly in regions where insurance policies may not provide full coverage for these devices. The cost of the stent, in addition to the surgery and follow-up care, may be prohibitive for specific patients and healthcare facilities.

• Obstacles to Reimbursement: Healthcare systems and geographical regions exhibit substantial disparities in reimbursement policies and coverage for venous stents. Healthcare professionals may be discouraged from performing venous stent procedures on patients in certain circumstances due to inadequate compensation.

• Alternative Treatments: Compression therapy and medication are two examples of alternative treatments that are available for venous disorders. These alternative treatments may be implemented in certain circumstances due to their perceived superiority or lower expense than venous catheters.

• Risks and Complications: Venous stents are susceptible to the same complications as any other medical device, such as migration, thrombosis, and stent fracture. These concerns may concern both patients and healthcare personnel, particularly when the potential risks are contrasted with the benefits of stent implantation.

• Procedure Complexity: The implantation of venous stents may involve complex steps requiring specialized knowledge and experience. This complexity may render these operations less accessible in certain healthcare environments and increase the risks and costs associated with the process.

• Regulatory Obstacles: The regulatory approval procedures for novel venous stent technologies can be complex and time-consuming, restricting patient access to new treatment alternatives and delaying the release of cutting-edge devices into the market.

• Limited Clinical Evidence: Despite the growing prevalence of venous stents, additional clinical evidence is still necessary to verify their safety and efficacy, particularly in the context of long-term outcomes. The lack of such data may impede patients’ and healthcare professionals’ widespread use of venous stents.

Venous Stents Market: Recent Developments

• Vesper Medical Inc., a company specializing in developing peripheral vascular devices that require minimally invasive surgery, was acquired by Royal Philips in May 2023. The agreement added a line of sophisticated venous stents for treating deep vein disease, further expanding Philips’ range of diagnostic and therapeutic devices.

• August 2020 (Approval): Bentley has obtained CE marking for its BeYond venous self-expanding stent system, an open cell Nitinol stent designed to treat acute and chronic symptomatic femoral or iliac occlusions with a diameter of 10-18 mm and a length of up to 150 mm.

Venous Stents Market: Dynamics

The venous system of the lower extremities is typically affected by deep vein disease, which results in the formation of a thrombosis in the deep vein of the calf and its subsequent dissemination. It is a prevalent venous thromboembolism (VTE) condition, with an annual incidence of 1.6 per 1,000.

Deep vein thrombosis (DVT) is a condition in which a blood clot develops in the deep veins of the body, usually in the legs. Still, it can also occur in the extremities, mesenteric, and cerebral veins. It is classified as a venous thromboembolic illness and is the third most significant cause of mortality from cardiovascular disease, following heart attack and stroke.

The majority of pulmonary embolism cases are caused by deep vein thrombosis, a perilous medical condition. It is administered to individuals with post-thrombotic syndrome (PTS) who have experienced a prior deep vein thrombosis (DVT) to alleviate symptoms of chronic pain and swelling and, in severe cases, to enhance wound repair.

Intravenous stenting is associated with a low risk of morbidity and mortality despite significant advancements in stent design for use in venous circulation, which drives the growth of the venous stent market.

Vein stenting is a valuable treatment option for venous disease. Research has demonstrated that vein stenting improves outcomes in treating chronic venous insufficiency, varicose veins, and deep vein thrombosis. Nevertheless, the exorbitant cost of venous stenting procedures has been a source of concern, particularly in comparison to other treatment options, such as lifestyle interventions and compression therapy.

Vein stenting is an effective treatment option for venous diseases, including chronic venous insufficiency and deep vein thrombosis. However, the cost of the procedure may be higher than that of other treatment options, such as compression therapy. In an effort to enhance the cost-effectiveness of venous stenting, innovative technologies and methodologies are being developed.

Venous Stents Market: Segmentation Analysis

By Technology

The market is divided into Iliac vein stent technology and wallstent technology. It is anticipated that the iliac vein stent technology will experience a substantial expansion during the review period due to its growing popularity, which may be attributed to its low cost, high radial force, MRI compatibility, and flexibility. In 2022, it held a dominant market share of 75.9%.

By Disease

The venous stents market is segmented into acute DVT, chronic DVT/PTS, NIVL/MTS, and other categories based on the underlying disease. Through 2030, the acute DVT segment is anticipated to experience a compound annual growth rate (CAGR) of 11.3%. The segmental perspective is expected to be bolstered by technological advancements in treatment methods and an increase in the number of individuals affected by DVT.

By Application

Based on their application, the venous stents market is classified into various categories, including leg, chest, abdomen, and others. The limb segment has achieved a dominant position in 2022, with a valuation of USD 551 million. The need for venous stents has been proliferated by the increasing prevalence of deep vein thrombosis, which has accelerated the segment growth.

Report Scope

Venous Stents Market: Regional Analysis

The global venous stents market is currently dominated by Europe, which is expected to exhibit a compound annual growth rate (CAGR) of 10.3% during the course of the analysis. The market is anticipated to expand in Europe due to the growing incidence of venous diseases.

In Europe, the safety and efficacy of venous stenting have been enhanced by using self-expanding stents, bioresorbable stents, coatings, and drug-eluting stents. Oxford University, Imperial College, and the University of Sheffield researchers collaborated with the technology company ThinkSono to develop a machine learning AI algorithm (AutoDVT) that could differentiate between DVT patients and those who were not diagnosed with DVT.

Over the forecast period, these developments are anticipated to augment market expansion. Furthermore, the venous stents market has experienced further growth due to the substantial increase in the number of minimally invasive venous procedures performed for complex venous diseases in recent years.

In 2024, the North American Venous Stents Market held a global market share of approximately 34.65%, with a valuation of USD 429.2 million. The regional market growth is primarily driven by the high prevalence of venous disease, particularly among the geriatric population, which has encouraged the adoption of the product in North America.

Numerous investigations have demonstrated that venous stenting yields favorable outcomes in treating chronic venous insufficiency, varicose veins, and deep vein thrombosis. The prevalence of venous diseases in North America is anticipated to drive the continued growth of the venous stent market share.

Additionally, advancements in stent technology have significantly influenced the pervasive adoption of venous stents in North America. Bioresorbable stents, self-expandable stents, drug-eluting stents, and coatings have all enhanced the safety and efficacy of venous stenting in North America. These developments are also contributing to the global market’s overall expansion.

Venous Stents Market: Significant Developments

• Philips announced the results of the VIVID trial in October 2023, which assessed the safety and efficacy of the Duo venous stent system. The VIVID trial was a single-arm, multicenter investigation that enrolled 162 patients with clinically significant venous outflow obstruction due to non-thrombotic, acute thrombotic, or chronic post-thrombotic conditions. The study was conducted at 30 sites in the United States and Poland.

• In May 2022, Becton, Dickinson, and Company announced that its Venovo venous stent system was re-launched in the United States market following a recall that was initiated in May 2021. The recall was instituted to outline the risks associated with stent migration.

• Bentley declared in July 2020 that its BeYond venous self-expanding stent system had been granted the CE Mark for commercial sale and clinical use in Europe. The novel device was initially introduced to a select group of renowned venous experts to provide them with firsthand experience. Subsequently, a full rollout was implemented at the beginning of 2021.

List of the prominent players in the Venous Stents Market:

• Abbott Laboratories
• Becton Dickinson and Company
• Bentley
• Boston Scientific Corporation
• Cardinal Health
• Cook Group Incorporated
• Koninklijke Philips N.V.
• Medtronic
• Shanghai MicroPort Endovascular MedTech(Group)Co. Ltd.
• W. L. Gore & Associates Inc.
• Others

The Venous Stents Market is segmented as follows:

By Technology

• Iliac Vein Stent Technology
• Wallstent Technology

By Disease

• Acute DVT
• Chronic DVT/PTS
• NIVL/MTS
• Others

By Application

• Leg
• Chest
• Abdomen
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America